Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021189 | 0.83 | NR4A2 (0.41) | NR4A2PARP1SMN1; SMN2MAPTHSP90AA1 | |
| SCHEMBL3373386 | 0.83 | SMN1; SMN2 (0.44) | NR4A2PARP1NPSR1SMN1; SMN2HSP90AA1 | |
| SCHEMBL13757342 | 0.82 | KDM4E (0.50) | NR4A2PARP1SMN1; SMN2NQO2HSP90AA1 | |
| SCHEMBL15483739 | 0.81 | NR4A2 (0.37) | NR4A2PARP1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL8145393 | 0.81 | NR4A2 (0.37) | NR4A2PARP1NPSR1SMN1; SMN2MAPT | |
| SCHEMBL13248807 | 0.80 | NR4A2 (0.40) | NR4A2PARP1MAPTKDM4E | |
| SCHEMBL1026984 | 0.78 | NR4A2 (0.65) | NR4A2PARP1MAPTHSP90AA1KDM4E | |
| SCHEMBL11403030 | 0.78 | NR4A2 (0.46) | NR4A2PARP1SMN1; SMN2NQO2MAPT | |
| SCHEMBL30601891 | 0.78 | NR4A2 (0.46) | NR4A2PARP1SMN1; SMN2NQO2MAPT | |
| SCHEMBL3372000 | 0.77 | MAP4K4 (0.37) | NR4A2PARP1NPSR1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | NR4A2 3771/4885PARP1 671/4885NPSR1 4462/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR4A2 3771/4885PARP1 671/4885NPSR1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.